Showing Results for
- Academic Journals (29)
Search Results
- 29
Academic Journals
- 29
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedNovartis is betting that optogenetics, a technology used by researchers to control cell signaling, is ready for the clinic. Author(s): Mark Ratner 1 Author Affiliations: (1) Tequesta, USA For $150 million plus...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedA Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00813-x. Author(s): Laura DeFrancesco 1 Author Affiliations: (1) Senior Editor, Nature Biotechnology, Correction to: Nature...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedWith drug pricing a priority for the US Biden administration, the biotech industry must clean up its act: stop profiteering from old products and stamp out anticompetitive practices. Author Affiliations: Late last...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor Affiliations: Grace Colón is president and CEO of InCarda Therapeutics. Her conversation with Nature Biotechnology covers growing up in San Juan, Puerto Rico; her love of musical theater; and how grad school at...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedPrime editing enables the introduction of virtually any small-sized genetic change without requiring donor DNA or double-strand breaks. However, evaluation of prime editing efficiency requires time-consuming experiments,...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedA quarterly snapshot of job expansions, reductions and availability in the biotech and pharma sectors. Author(s): Michael Francisco 1 Author Affiliations: (1) Senior Editor, Nature Biotechnology, Roche announced...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Laura DeFrancesco 1 Author Affiliations: (1) Senior Editor, Nature Biotechnology, 2020 stands out as one of the best years ever for biotech financing across the globe. Stock indices remained up through...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedSingle-cell barcoding technologies enable genome sequencing of thousands of individual cells in parallel, but with extremely low sequencing coverage (<0.05×) per cell. While the total copy number of large multi-megabase...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor Affiliations: Atalanta Therapeutics launched in January, announcing partnerships with Biogen and Genentech and $110 million in series A financing. The company was born from work described in a 2019 Nature...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Tesfaye (Shiferaw) Sida 1 Author Affiliations: (1) International Maize and Wheat Improvement Center (CIMMYT), Sustainable Intensification Program (SIP), CIMMYT-Ethiopia, Addis Ababa, Ethiopia To the...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedMonitoring the T cell receptor (TCR) repertoire in health and disease can provide key insights into adaptive immune responses, but the accuracy of current TCR sequencing (TCRseq) methods is unclear. In this study, we...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Allison Tong 1 , Tania C. Sorrell 2 3 , Andrew J. Black 4 , Corinne Caillaud 5 6 7 , Wojciech Chrzanowski 5 6 , Eugena Li 6 , David Martinez-Martin 6 8 , Alistair McEwan 6 8 , Rex Wang 6 , Alice Motion 6 9 ,...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor Affiliations: Amgen has teamed up with University of Michigan spinout Evoq Therapeutics to develop a dendritic-cell-based immunotherapy for autoimmune diseases. The $240 million deal gives Amgen access to Evoq's...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Valentine Svensson 1 Author Affiliations: (1) Serqet Therapeutics Inc., Computational Biology & Data Science, Cambridge, USA replying to Y. Cao et al. Nature Biotechnology...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedDetermining the spatial organization of chromatin in cells mainly relies on crosslinking-based chromosome conformation capture techniques, but resolution and signal-to-noise ratio of these approaches is limited by...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedOnce a neglected biological phenomenon, condensates are attracting interest from small companies and large pharmas. Author(s): Elie Dolgin 1 Author Affiliations: (1) Somerville, USA Three startups debuted in late...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedThe translational power of human microbiome studies is limited by high interindividual variation. We describe a dimensionality reduction tool, compositional tensor factorization (CTF), that incorporates information from...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Orit Rozenblatt-Rosen 1 , Jay W. Shin 2 , Jennifer E. Rood 1 , Anna Hupalowska 1 , Kristin Ardlie 7 , Menna Clatworthy 8 9 , Piero Carninci 10 , Wolfgang Enard 11 , William Greenleaf 12 , Holger Heyn 5 ,...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedCellular metabolism regulates immune cell activation, differentiation and effector functions, but current metabolic approaches lack single-cell resolution and simultaneous characterization of cellular phenotype. In this...
-
From:Nature Biotechnology (Vol. 39, Issue 2) Peer-ReviewedAuthor(s): Dmitry Kobak 1 , George C. Linderman 2 Author Affiliations: (1) Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany (2) Applied Mathematics Program, Yale University, New Haven,...